A 24-month randomized trial tested high-dose oral lipoic acid in people with primary or secondary progressive multiple sclerosis (MS). The supplement did not improve walking speed or other clinical outcomes compared with placebo. MRI findings were mixed and difficult to interpret, while kidney-related adverse effects raised an important safety concern.
The phase 2 trial enrolled 115 adults at multiple sites in the United States and Canada. Participants received either 1,200 milligrams of oral lipoic acid daily or a placebo for two years. More than half were also using an MS disease-modifying therapy.
The primary goal was to determine whether lipoic acid slowed decline in walking speed. Researchers also evaluated walking endurance, falls, disability, cognition, patient-reported symptoms, MRI measures and adverse events.
Lipoic acid did not slow the decline in timed walking speed. Researchers also found no meaningful advantage for walking endurance, falls, overall neurologic disability, cognition, pain, sleep, fatigue, activity or social participation. More participants stopped the study early in the lipoic-acid group than in the placebo group.
Whole-brain volume appeared more stable in the lipoic-acid group, but the difference was not statistically significant and became smaller after an additional adjustment. Deep gray-matter volume favored lipoic acid, while total T2 lesion volume increased more in the lipoic-acid group. The investigators described these imaging findings as challenging to interpret.
An MRI measurement is a research biomarker; it is not by itself proof that a treatment helps patients feel or function better. In this trial, the imaging signals did not translate into better mobility, cognition or patient-reported outcomes.
Protein in the urine occurred more often with lipoic acid, and the researchers identified a treatment-related case of a form of membranous nephropathy. Kidney-function declines and nausea were also more common in the lipoic-acid group. Monitoring was increased during the trial because of these events.
This matters because the studied dose was high and lipoic acid is available without a prescription. “Over the counter” does not mean risk-free, and the trial protocol’s laboratory monitoring cannot be replicated by self-treatment.
Lipoic acid is not a substitute for an MS disease-modifying therapy, rehabilitation or neurologic care. People with MS should not start the 1,200-milligram regimen used in this trial on their own. Anyone currently using lipoic acid should tell their neurologist and pharmacist, including the product, dose and frequency, so potential risks and appropriate monitoring can be reviewed.
Seek medical advice promptly for swelling, foamy urine, changes in urination or other new symptoms. Do not add another supplement to “balance” lipoic acid without professional guidance; doing so can add interactions and make side effects harder to identify.
This trial did not show that lipoic acid improved walking or other clinical outcomes in progressive MS. Although some MRI findings may guide future research, they do not establish a patient benefit, and the kidney-related risks are clinically important. The evidence does not support presenting lipoic acid as a proven MS treatment.